AbbVie slides as Coherus plans 'lowest list price' Humira biosimilar - InvestingChannel

AbbVie slides as Coherus plans ‘lowest list price’ Humira biosimilar

Shares of AbbVie (ABBV) are down $5.44, or 4%, to $132.52 in early trading after Coherus BioSciences (CHRS) announced that the company plans to launch Yusimry in July with a list price of $995 per carton, which it calls “the lowest price announced to date of any adalimumab offering in the United States.” Denny Lanfear, Coherus CEO, said: “Our Yusimry list price is a clear response to the challenges and needs of patients faced with high-cost adalimumab treatments today. We believe there is a large, unmet need for improved access and affordability in the U.S. health care system that Yusimry can address with this pricing.” In addition, Mark Cuban Cost Plus Drug Company and Coherus announced plans to offer Mark Cuban Cost Plus Drug Company customers Yusimry, a biosimilar of Humira, in July, with Lanfear adding: “This agreement is part of our biosimilar strategy to leverage our excellence in manufacturing and supply chain management to deliver safe and effective biosimilars with ensured, reliable supply.” Mark Cuban Cost Plus Drug Company plans to offer Yusimry to its customers at a price of $569.27 plus dispensing and shipping fees. In morning trading, Coherus shares are down about 2% to $4.02 following the announcements.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire